Use este identificador para citar ou linkar para este item: https://repositorio.inpa.gov.br/handle/1/16591
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorCáceres, Diego H.-
dc.contributor.authorAdenis, Antoine A.-
dc.contributor.authorSouza, João Vicente Braga de-
dc.contributor.authorGómez, Beatriz L.-
dc.contributor.authorCruz, Kátia Santana-
dc.contributor.authorPasqualotto, Alessandro-
dc.contributor.authorRavasi, Giovanni-
dc.contributor.authorPérez, Freddy-
dc.contributor.authorChiller, Tom M.-
dc.contributor.authorLacerda, Marcus Vinícius Guimarães de-
dc.contributor.authorNacher, Mathieu-
dc.date.accessioned2020-06-15T21:35:20Z-
dc.date.available2020-06-15T21:35:20Z-
dc.date.issued2019-
dc.identifier.urihttps://repositorio.inpa.gov.br/handle/1/16591-
dc.description.abstractPurpose of Review: The aim of this report is to summarize the conclusions of the II Regional Meeting on Histoplasmosis in the Americas held in Manaus, Brazil, on March 22–24, 2019. Recent Findings: Persons living with advanced HIV are at high risk for developing histoplasmosis. Clinical signs and symptoms of this disease are often non-specific, making it difficult to establish a diagnosis. Although with the recent technological advances, in vitro diagnostics and medicines for histoplasmosis are often not available in many regions around the world. In addition, histoplasmosis is often not included in HIV care and treatment programs, resulting in inadequate health system planning and missed opportunities to save lives. Summary: The II Regional Meeting on Histoplasmosis in the Americas gathered a multidisciplinary audience. Developed recommendations to be included in the WHO guidelines for diagnosis and treatment of histoplasmosis in advanced HIV were the product of this meeting, and guidelines are aimed to be published in early 2020. © 2019, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.en
dc.language.isoenpt_BR
dc.relation.ispartofVolume 13, Número 4, Pags. 244-249pt_BR
dc.rightsRestrito*
dc.subjectItraconazoleen
dc.subjectAcquired Immune Deficiency Syndromeen
dc.subjectClinical Featureen
dc.subjectConsensus Developmenten
dc.subjectDiagnostic Testen
dc.subjectDisease Severityen
dc.subjectDisease Surveillanceen
dc.subjectHealth Care Organizationen
dc.subjectHealth Care Planningen
dc.subjectHealth Programen
dc.subjectHigh Risk Patienten
dc.subjectHistoplasmosisen
dc.subjectHumanen
dc.subjectHuman Immunodeficiency Virus Infected Patienten
dc.subjectHuman Immunodeficiency Virus Infectionen
dc.subjectIn Vitro Studyen
dc.subjectInternational Cooperationen
dc.subjectMedical Technologyen
dc.subjectPatient Careen
dc.subjectPractice Guidelineen
dc.subjectReviewen
dc.subjectSymptomen
dc.subjectWestern Hemisphereen
dc.subjectWorld Health Organizationen
dc.titleThe Manaus Declaration: Current Situation of Histoplasmosis in the Americas, Report of the II Regional Meeting of the International Histoplasmosis Advocacy Groupen
dc.typeArtigopt_BR
dc.identifier.doi10.1007/s12281-019-00365-3-
dc.publisher.journalCurrent Fungal Infection Reportspt_BR
Aparece nas coleções:Artigos

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.